MXCT Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue:: $7.3 million, down 15% from $8.5 million in Q2 2025.

Core Revenue:: $6.5 million, a 21% decrease from $8.2 million in the prior year.

Instrument Revenue:: $1.8 million, down from $2.1 million year-over-year.

License Revenue:: $1.8 million, down from $2.6 million.

Processing Assembly Revenue:: $2.3 million, down from $3.1 million, though flat when excluding prior year tariff-driven purchases.

SPL Program Related Revenue:: $0.8 million, up from $0.3 million year-over-year, primarily driven by royalties.

Gross Margin:: 77%, down from 82% in Q2 2025, impacted by a higher proportion of lower-margin instrument revenue.

Operating Expenses:: $15.8 million, down 25% from $21.2 million in Q2 2025, reflecting cost management efforts.

Cash Position:: $141.9 million in cash and investments, with no debt.

2Strategic Updates and Business Highlights

Partnership with Genentech:: A significant multiplatform technology license agreement was established, allowing Genentech access to MaxCyte's ExPERT GTx platform and other technologies for multiple cell therapy programs. This partnership is expected to generate long-term value and diversify revenue streams.

R&D Investments:: Continued investment in platforms like ExPERT DTx and SeQure to enhance customer engagement from early discovery to commercial manufacturing.

Instrument Adoption:: Positive early traction for the DTx platform across discovery and optimization workflows, with expectations for continued growth.

3Forward Guidance and Outlook

2026 Revenue Guidance:: Reiterated total revenue expected between $30 million to $32 million, with core revenue of $25 million to $27 million and SPL milestones and royalties of $5 million.

Second Half Expectations:: Anticipated low single-digit year-over-year revenue growth, driven by instrument placements and stable processing assembly demand. Q4 is expected to be slightly higher than Q3 due to typical year-end budget flush dynamics.

4Bad News, Challenges, or Points of Concern

Revenue Decline:: Notable year-over-year decreases in total and core revenue, primarily due to inventory drawdowns by the largest customer and the discontinuation of several partner clinical programs.

Gross Margin Pressure:: Decreased gross margins due to a shift in product mix towards lower-margin instrument sales.

Market Environment:: While there is stabilization in the cell therapy market, it has not returned to previous highs, and funding remains cautious, particularly in biotech.

5Notable Q&A Insights

Instrument Revenue Sources:: Instrument revenue growth was broad-based across research, process development, and clinical applications, with no specific product driving the increase.

Competitive Landscape:: No significant changes in competition were noted; MaxCyte continues to displace competitors and maintain a strong position in the market.

Academic Partnerships:: There is growing traction in academic partnerships, particularly with institutions pursuing clinical trials, which could lead to future SPLs.

International Opportunities:: MaxCyte is actively exploring opportunities in the Asia Pacific region, where investments in cell therapy are increasing, and is building infrastructure to support growth in these markets. Overall, while MaxCyte faces some challenges, particularly with revenue declines and margin pressures, strategic partnerships and ongoing investments in R&D position the company for potential growth in the second half of 2026 and beyond.